what is a glp-1 program Drug Savings: Complete Guide for How to Save on Ozempic, Wegovy, and More 🚨 A new Medicare program

Our model brings together access to providers, technology infrastructure, and a modern consumer experience across verticals like medical weight loss, hormone therapy, wellness, and medspa services.

By inhibiting the latent GDF8, SRK-015 achieves high selectivity with minimal side effects

A comprehensive FAQ article about all things gastroparesis

Our platform was designed specifically to help patients lose weight and keep it off,

Big pharma is currently facing a potential bubble effect due to the surging demand for weight loss and diabetes drugs, as revealed in a report by Deloitte released on Monday

The GLP-1 receptor agonist semaglutide reduces risks of kidney function loss, kidney failure, cardiovascular events, cardiovascular death and all-cause mortality in people with CKD and T2DM Ongoing clinical and mechanistic studies are expected to expand use of GLP-1 receptor agonists, GLP-1/GIP and other metabolic hormones for the treatment of CKD At the moment the most complete data is available for semaglutide from SUSTAIN-6 and FLOW trial which is the only trial with primary renal outcome in T2DM patients out of all GLP-1 RA Very good data for renal outcomes as secondary ones available for GLP-1 RAs dulaglutide and liraglutide and GLP-1/GIP RA tirzepatide, Very interesting and positive data from mechanistic REMODEL trial with semaglutide in T2DM patients presented but not yet published (reduced perirenal fat, rernal fibrosis and much more) Based on following excellent papers: #glp1 #gip #semaglutide #tirzepatide #liraglutide #dulaglutide #kidney #ckd #chronickidneydisease #cardiovascularcomplications